Silence Therapeutics plc shareholders approved To approve the application of Article 159 of the Company's articles of association from the conclusion of this AGM to the conclusion of the next annual general meeting of the Company. at the 2026-06-16 meeting.
“Resolution 9 : To approve the application of Article 159 of the Company's articles of association from the conclusion of this AGM to the conclusion of the next annual general meeting of the Company. The votes were cast as follows: For Against Abstain 48,307,317 9,333 4,405,761”
Shareholder Votes
Silence Therapeutics plc shareholders approved To approve the directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 32 to 54 (inclusive) of the 2025 U.K. Annual Report. at the 2026-06-16 meeting.
“Resolution 8 : To approve the directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 32 to 54 (inclusive) of the 2025 U.K. Annual Report. The votes were cast as follows: For Against Abstain 48,251,875 66,518 4,404,018”
Shareholder Votes
Silence Therapeutics plc shareholders approved To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). at the 2026-06-16 meeting.
“Resolution 7 : To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). The votes were cast as follows: For Against Abstain 52,715,076 3,108 4,077”
Shareholder Votes
Silence Therapeutics plc shareholders approved To authorize the Audit & Risk Committee to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2026. at the 2026-06-16 meeting.
“Resolution 6 : To authorize the Audit & Risk Committee to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 52,714,237 6,155 1,869”
Shareholder Votes
Silence Therapeutics plc shareholders approved To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. at the 2026-06-16 meeting.
“Resolution 5 : To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. The votes were cast as follows: For Against Abstain 52,718,407 2,885 1,119”
Shareholder Votes
Silence Therapeutics plc shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-16 meeting.
“Resolution 4 : To ratify the appointment of PricewaterhouseCoopers LLP as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 52,718,407 2,885 1,119”
Shareholder Votes
Silence Therapeutics plc shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. at the 2026-06-16 meeting.
“Resolution 3 : To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: For Against Abstain 48,234,208 73,667 4,414,536”
Shareholder Votes
Silence Therapeutics plc shareholders approved To re-appoint as a director of the Company James Ede-Golightly. at the 2026-06-16 meeting.
“Resolution 2 : To re-appoint as a director of the Company James Ede-Golightly. The votes were cast as follows: For Against Abstain 52,112,045 605,683 4,680”
Shareholder Votes
Silence Therapeutics plc shareholders approved To re-appoint as a director of the Company Rhonda Hellums. at the 2026-06-16 meeting.
“Resolution 1 : To re-appoint as a director of the Company Rhonda Hellums. The votes were cast as follows: For Against Abstain 47,160,731 5,557,090 4,680”
“The Sales Agreement replaces the prior Open Market Sale Agreement SM , dated October 15, 2021, by and between the Company and Jefferies (the “Prior Sales Agreement’), which was terminated as of May 18, 2026 pursuant to the terms of the Sales Agreement.”
Material Agreements
Silence Therapeutics plc entered into Sales Agreement with Jefferies LLC valued at aggregate offering amount not exceeding the Maximum Program Amount (effective 2026-05-18).
“On May 18, 2026, Silence Therapeutics plc (the “Company” or “we”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”).”
Earnings Releases
Silence Therapeutics plc reported the first quarter ended March 31, 2026 results: revenue $0.4 million, net income Net loss was $15.0 million, or $0.11 basic and diluted net loss per share, EPS $0.11 basic and diluted net loss per share.
“cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1”
Earnings Releases
Silence Therapeutics plc reported the fourth quarter and full year ended December 31, 2025 results: revenue $0.6 million, net income $88.6 million, EPS $0.63 basic and diluted net loss per share.
“Full Year 2025 Financial Results • Cash Position: Cash, cash equivalents, and short-term investments were $85.1 million as of December 31, 2025. This includes cash and cash equivalents of $11.3 million and short-term investments of $73.8 million. • Collaboration Revenue: Collaboration revenue was $0.6 million for the year ended December 31, 2025, compared to $43.3 million for the year ended December 31, 2024. The decrease for 2025 was primarily due to revenue associated with the Hansoh collaboration that concluded in 2024 and a $17.4 million decrease in revenue related to the AstraZeneca collaboration. • R&D Expenses: Research and development (R&D) expenses were $67.8 million for the year ended December 31, 2025, compared to $67.9 million for the year ended December 31, 2024. • G&A Expenses: General and administrative (G&A) expenses were $22.3 million for the year ended December 31, 2025, compared to $26.9 million for the year ended December 31, 2024. The decrease for 2025 was primaril”
Tim McInerney was appointed as Director at Silence Therapeutics plc.
“On May 5, 2025, upon the recommendation of the Nominations Committee, the Board appointed Tim McInerney to serve as a director of the Company, effective immediately.”
James Ede-Golightly departed as Director at Silence Therapeutics plc.
“On May 5, 2025, James Ede-Golightly notified the board of directors (the “ Board ”) of Silence Therapeutics plc (the “ Company ”) of his decision to retire from the Board following the end of his current term, which expires at the end of the Company’s 2025 Annual General Meeting of Shareholders, which is anticipated to be held on June 26, 2025 (the “ 2025 AGM ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.